Department of Thoracic Surgery, Diseases of the Esophagus and Lung Transplantation, North Hospital, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
Department of Anesthesiology and Intensive Care Medicine, North Hospital, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
JAMA Surg. 2023 Dec 1;158(12):1255-1263. doi: 10.1001/jamasurg.2023.5228.
In minimally invasive thoracic surgery, paravertebral block (PVB) using ultrasound (US)-guided technique is an efficient postoperative analgesia. However, it is an operator-dependent process depending on experience and local resources. Because pain-control failure is highly detrimental, surgeons may consider other locoregional analgesic options.
To demonstrate the noninferiority of PVB performed by surgeons under video-assisted thoracoscopic surgery (VATS), hereafter referred to as PVB-VATS, as the experimental group compared with PVB performed by anesthesiologists using US-guided technique (PVB-US) as the control group.
DESIGN, SETTING, AND PARTICIPANTS: In this single-center, noninferiority, patient-blinded, randomized clinical trial conducted from September 8, 2020, to December 8, 2021, patients older than 18 years who were undergoing a scheduled minimally invasive thoracic surgery with lung resection including video-assisted or robotic approaches were included. Exclusion criteria included scheduled open surgery, any antalgic World Health Organization level greater than 2 before surgery, or a medical history of homolateral thoracic surgery. Patients were randomly assigned (1:1) to an intervention group after general anesthesia. They received single-injection PVB before the first incision was made in the control group (PVB-US) or after 1 incision was made under thoracoscopic vision in the experimental group (PVB-VATS).
PVB-VATS or PVB-US.
The primary end point was mean 48-hour post-PVB opioid consumption considering a noninferiority range of less than 7.5 mg of opioid consumption between groups. Secondary outcomes included time of anesthesia, surgery, and operating room occupancy; 48-hour pain visual analog scale score at rest and while coughing; and 30-day postoperative complications.
A total of 196 patients were randomly assigned to intervention groups: 98 in the PVB-VATS group (mean [SD] age, 64.6 [9.5] years; 53 female [54.1%]) and 98 in the PVB-US group (mean [SD] age, 65.8 [11.5] years; 62 male [63.3%]). The mean (SD) of 48-hour opioid consumption in the PVB-VATS group (33.9 [19.8] mg; 95% CI, 30.0-37.9 mg) was noninferior to that measured in the PVB-US group (28.5 [18.2] mg; 95% CI, 24.8-32.2 mg; difference: -5.4 mg; 95% CI, -∞ to -0.93; noninferiority Welsh test, P ≤ .001). Pain score at rest and while coughing after surgery, overall time, and postoperative complications did not differ between groups.
PVB placed by a surgeon during thoracoscopy was noninferior to PVB placed by an anesthesiologist using ultrasonography before incision in terms of opioid consumption during the first 48 hours.
ClinicalTrials.gov Identifier: NCT04579276.
在微创胸外科中,采用超声(US)引导技术的椎旁阻滞(PVB)是一种有效的术后镇痛方法。然而,它是一种依赖于经验和当地资源的操作者依赖过程。由于疼痛控制失败的危害极大,外科医生可能会考虑其他局部区域镇痛选择。
证明在视频辅助胸腔镜手术(VATS)下由外科医生进行的 PVB(简称 PVB-VATS)与由麻醉师采用 US 引导技术进行的 PVB(简称 PVB-US)相比,作为实验组,其作为术后镇痛的非劣效性。
设计、设置和参与者:这是一项单中心、非劣效性、患者盲法、随机临床试验,于 2020 年 9 月 8 日至 2021 年 12 月 8 日进行,纳入了年龄大于 18 岁、计划行微创胸腔镜肺切除术(包括视频辅助或机器人方法)的患者。排除标准包括计划行开放性手术、术前任何疼痛程度为世界卫生组织(WHO)镇痛分级 2 级以上、或同侧胸部手术史。患者在全身麻醉后被随机分配(1:1)到干预组。在对照组(PVB-US)中,在第一切口前给予单次注射 PVB;在实验组(PVB-VATS)中,在胸腔镜视野下完成第一切口后给予单次注射 PVB。
PVB-VATS 或 PVB-US。
考虑组间阿片类药物消耗的非劣效性范围小于 7.5 mg,48 小时内 PVB 阿片类药物消耗的平均值。次要结局包括麻醉、手术和手术室占用时间;休息和咳嗽时的 48 小时疼痛视觉模拟评分;以及 30 天术后并发症。
共有 196 名患者被随机分配到干预组:98 名患者接受 PVB-VATS(平均[SD]年龄,64.6[9.5]岁;53 名女性[54.1%]),98 名患者接受 PVB-US(平均[SD]年龄,65.8[11.5]岁;62 名男性[63.3%])。PVB-VATS 组(33.9[19.8]mg;95%CI,30.0-37.9mg)48 小时阿片类药物消耗量的平均值非劣于 PVB-US 组(28.5[18.2]mg;95%CI,24.8-32.2mg;差异:-5.4mg;95%CI,-∞至-0.93;非劣效性威尔士检验,P≤.001)。术后休息和咳嗽时的疼痛评分、总时间和术后并发症在两组间无差异。
在胸腔镜手术期间由外科医生进行的 PVB 在术后前 48 小时的阿片类药物消耗方面与在切口前由麻醉师采用 US 引导技术进行的 PVB 相比非劣效。
ClinicalTrials.gov 标识符:NCT04579276。